No retraction, correction or concern found when last checked on Oct 17, 2026.

Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19

Joydeb Majumder, Tamara Minko

The AAPS Journal · 2021 · Review · CC BY

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made a serious public health threat worldwide with millions of people at risk in a growing number of countries. Though there are no clinically approved antiviral drugs and vaccines for COVID-19, attempts are ongoing for clinical trials of several known antiviral drugs, their combination, as well as development of vaccines in patients with confirmed COVID-19. This review focuses on the latest approaches to diagnostics and therapy of COVID-19. We have summarized recent progress on the conventional therapeutics such as antiviral drugs, vaccines, anti-SARS-CoV-2 antibody treatments, and convalescent plasma therapy which are currently under extensive research and clinical trials for the treatment of COVID-19. The developments of nanoparticle-based therapeutic and diagnostic approaches have been also discussed for COVID-19. We have assessed recent literature data on this topic and made a summary of current development and future perspectives.

References 184

1.
Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007;20(4):660-694.
Not in our library10.1128/cmr.00023-07
2.
Girard MP, Tam JS, Assossou OM, Kieny MP. The 2009 a (H1N1) influenza virus pandemic: a review. Vaccine. 2010;28(31):4895-4902.
Not in our library10.1016/j.vaccine.2010.05.031
3.
Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386(9997):995-1007.
Not in our library10.1016/s0140-6736(15)60454-8
4.
Oleribe OO, Salako BL, Ka MM, Akpalu A, McConnochie M, Foster M, et al. Ebola virus disease epidemic in West Africa: lessons learned and issues arising from West African countries. Clin Med. 2015;15:54-57.
Not in our library10.7861/clinmedicine.15-1-54
5.
Agumadu VC, Ramphul K. Zika virus: a review of literature. Cureus. 2018;10(7):e3025.
Not in our library10.7759/cureus.3025
6.
World Health, Organization. Novel coronavirus (2019-nCoV): situation report, 1. Geneva: World Health Organization; 2020. https://apps.who.int/iris/handle/10665/330760. Accessed 2020-01-21.
Not in our library
7.
The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 · 2020
No notice
8.
Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern · 2020
No notice
9.
WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health, Organization (WHO); 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virusthat-causes-it.
Not in our library
10.
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed. 2020;91((1):157-160.
Not in our library10.23750/abm.v91i1.9397
11.
Coronavirus disease (COVID-19) pandemic. World Health Organization; 2020 [cited 2020 10/31/2020]; Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019?gclid=Cj0KCQjwlvT8BRDeARIsAACRFiW_AoKe8cr7J7MyGq46ojb4LEDnznIAUBkEXISSPxIfKCLbfmxjYgUaAriBEALw_wcB.
Not in our library
12.
Asymptomatic and Human-to-Human Transmission of SARS-CoV-2 in a 2-Family Cluster, Xuzhou, China · 2020
No notice
13.
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.
Not in our library10.1056/nejmoa2001017
14.
Su S, Wong G, Shi W, Liu J, Lai ACK, Zhou J, Liu W, Bi Y, Gao GF. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490-502.
Not in our library10.1016/j.tim.2016.03.003
15.
Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: are they closely related? Clin Microbiol Infect. 2020;26(6):729-734.
Not in our library10.1016/j.cmi.2020.03.026
16.
Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li VYC, et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano. 2020;14(4):3822-3835.
Not in our library10.1021/acsnano.0c02624
17.
Khan I, Ahmed Z, Sarwar A, Jamil A, Anwer F. The potential vaccine component for COVID-19: a comprehensive review of global vaccine development efforts. Cureus. 2020;12(6):e8871.
Not in our library10.7759/cureus.8871
18.
Goldman-Israelow B. Coronavirus replication cycle (template). BioRender.com; 2020 [cited 2020 11/01/2020]; Available from: https://app.biorender.com/biorender-templates/figures/5e99f5395fd61e0028682c01/t-5e56d97d1b689000850f8f93-coronavirus-replication-cycle.
Not in our library
19.
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, Li SB, Wang HY, Zhang S, Gao HN, Sheng JF, Cai HL, Qiu YQ, Li LJ. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
Not in our library10.1136/bmj.m606
20.
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513.
Not in our library10.1016/s0140-6736(20)30211-7
21.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323:1239-1242.
Not in our library10.1001/jama.2020.2648
22.
Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, et al. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol. 2020;115(6):916-923.
Not in our library10.14309/ajg.0000000000000664
23.
Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115(5):766-773.
Not in our library10.14309/ajg.0000000000000620
24.
Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of COVID-19 in children in early January 2020 in Wuhan, China. N Engl J Med. 2020;382:1370-1371.
Not in our library10.1056/nejmc2003717
25.
Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al. SARS-CoV-2 infection in children. N Engl J Med. 2020;382:1663-1665.
Not in our library10.1056/nejmc2005073
26.
Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706-711.
Not in our library10.1007/s11427-020-1661-4
27.
Wang Y, Liu Y, Liu L, Wang X, Luo N, Li L. Clinical outcomes in 55 patients with severe acute respiratory syndrome coronavirus 2 who were asymptomatic at hospital admission in Shenzhen, China. J Infect Dis. 2020;221(11):1770-1774.
Not in our library10.1093/infdis/jiaa119
28.
Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020 · 2020
Corrected
29.
Pan X, Chen D, Xia Y, Wu X, Li T, Ou X, et al. Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect Dis. 2020;20(4):410-411.
Not in our library10.1016/s1473-3099(20)30114-6
30.
Sakurai A, Sasaki T, Kato S, Hayashi M, Tsuzuki SI, Ishihara T, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020. 10.1056/NEJMc2013020.
Not in our library10.1056/nejmc2013020
31.
Wang Y, Kang H, Liu X, Tong Z. Asymptomatic cases with SARS-CoV-2 infection. J Med Virol. 2020. 10.1002/jmv.25990.
Not in our library10.1002/jmv.25990
32.
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41-58.
Not in our library10.1038/nrd.2018.168
33.
Bauchner H, Fontanarosa PB. Randomized clinical trials and COVID-19: managing expectations. JAMA. 2020;323(22):2262-2263.
Not in our library10.1001/jama.2020.8115
34.
Ahidjo BA, Loe MWC, Ng YL, Mok CK, Chu JJH. Current perspective of antiviral strategies against COVID-19. ACS Infect Dis. 2020;6:1624-1634.
Not in our library10.1021/acsinfecdis.0c00236
35.
Malik S, Gupta A, Zhong X, Rasmussen TP, Manautou JE, Bahal R. Emerging therapeutic modalities against COVID-19. Pharmaceuticals (Basel). 2020;13(8):188.
Not in our library10.3390/ph13080188
36.
COVID-19 Vaccine tracker. 2020 [cited 2020 08/08/2020]; Available from:https://biorender.com/covid-vaccine-tracker.
Not in our library
37.
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China · 2020
No notice
38.
Correia IR. Stability of IgG isotypes in serum. mAbs. 2010;2(3):221-232.
Not in our library10.4161/mabs.2.3.11788
39.
Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model · 2020
No notice
40.
Liu C, Zhou Q, Li Y, Garner LV, Watkins SP, Carter LJ, et al. Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci. 2020;6(3):315-331.
Not in our library10.1021/acscentsci.0c00272
41.
Chinese Clinical Trial Registry. A randomized controlled trial for the efficacy and safety of baloxavir marboxil, favipiravir tablets in novel coronavirus pneumonia (COVID-19) patients who are still positive on virus detection under the current antiviral therapy. 2020. https://www.chictr.org.cn/showprojen.aspx?proj=49013. Accessed 11/23/2020.
Not in our library
42.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 - preliminary report. N Engl J Med 2020. 10.1056/NEJMoa2007764.
Not in our library10.1056/nejmc2022236
43.
Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72-73.
Not in our library10.5582/bst.2020.01047
44.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1):105949.
Not in our library10.1016/j.ijantimicag.2020.105949
45.
Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, et al. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020;56:106114.
Not in our library10.1016/j.ijantimicag.2020.106114
46.
Vankadari N. Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents. 2020;56(2):105998.
Not in our library10.1016/j.ijantimicag.2020.105998
47.
Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381-385.
Not in our library10.1038/nature17180
48.
Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653.
Not in our library10.1126/scitranslmed.aal3653
49.
Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease · 2018
No notice
50.
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19 · 2020
Not checked
51.
Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D’Arminio Monforte A, Ismail S, Kato H, Lapadula G, L’Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate use of remdesivir for patients with severe COVID-19. N Engl J Med. 2020;382(24):2327-2336.
Not in our library10.1056/nejmoa2007016
52.
Spinner CD, Gottlieb RL, Criner GJ, Arribas Lopez JR, Cattelan AM, Soriano Viladomiu A, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324(11):1048-1057.
Not in our library10.1001/jama.2020.16349
53.
FDA approves first treatment for COVID-19. Food and Drug Administration (FDA); 2020 [updated October 22, 2020; cited 2020 11/01/2020]; Available from:https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19.
Not in our library
54.
Huang L, Zhang L, Liu Y, Luo R, Zeng L, Telegina I, et al. Arbidol for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2017;2017:CD011489.
Not in our library10.1002/14651858.cd011489.pub2
55.
Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The antiviral drug arbidol inhibits Zika virus. Sci Rep. 2018;8(1):8989.
Not in our library10.1038/s41598-018-27224-4
56.
Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA, Shoemaker CJ, et al. Arbidol and other low-molecular-weight drugs that inhibit Lassa and Ebola viruses. J Virol. 2019;93:e02185-e02118.
Not in our library10.1128/jvi
57.
Kadam RU, Wilson IA. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc Natl Acad Sci U S A. 2017;114(2):206-214.
Not in our library10.1073/pnas.1617020114
58.
Teissier E, Zandomeneghi G, Loquet A, Lavillette D, Lavergne JP, Montserret R, et al. Mechanism of inhibition of enveloped virus membrane fusion by the antiviral drug Arbidol. PLoS One. 2011;6(1):e15874.
Not in our library10.1371/journal.pone.0015874
59.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71.
Not in our library10.5582/bst.2020.01020
60.
Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020;38(4):379-381.
Not in our library10.1038/d41587-020-00003-1
61.
Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study. Clin Microbiol Infect. 2020;26(7):917-921.
Not in our library10.1016/j.cmi.2020.04.026
62.
Chen J, Lin S, Niu C, Xiao Q. Clinical evaluation of Shufeng Jiedu Capsules combined with umifenovir (Arbidol) in the treatment of common-type COVID-19: a retrospective study. Expert Rev Respir Med. 2020:1–9. 10.1080/17476348.2020.1822741.
Not in our library10.1080/17476348.2020.1822741
63.
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020;209:107512.
Not in our library10.1016/j.pharmthera.2020.107512
64.
RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution · 2018
No notice
65.
Shu B, Gong P. Structural basis of viral RNA-dependent RNA polymerase catalysis and translocation. Proc Natl Acad Sci U S A. 2016;113(28):E4005-E4014.
Not in our library10.1073/pnas.1602591113
66.
Nagata T, Lefor AK, Hasegawa M, Ishii M. Favipiravir: a new medication for the Ebola virus disease pandemic. Disaster Med Public Health Prep. 2015;9(1):79-81.
Not in our library10.1017/dmp.2014.151
67.
Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38(8):653-671.
Not in our library10.1007/s40261-018-0656-y
68.
Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55(5):105938.
Not in our library10.1016/j.ijantimicag.2020.105938
69.
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro · 2020
No notice
70.
Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69.
Not in our library10.1186/1743-422x-2-69
71.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58-60.
Not in our library10.5582/ddt.2020.01012
72.
Zhu RF, Gao YL, Robert SH, Gao JP, Yang SG, Zhu CT. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19). J Transl Med. 2020;18(1):274.
Not in our library10.1186/s12967-020-02442-5
73.
A Review of SARS-CoV-2 and the Ongoing Clinical Trials · 2020
No notice
74.
The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus · 2020
No notice
75.
Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-1578.
Not in our library10.1016/s0140-6736(20)31022-9
76.
NIH Clinical Trials. A trial of remdesivir in adults with mild and moderate COVID-19. https://clinicaltrials.gov/ct2/show/NCT04252664. 2020.
Not in our library
77.
Lythgoe MP, Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363-382.
Not in our library10.1016/j.tips.2020.03.006
78.
NIH Clinical Trials. A prospective/retrospective, randomized controlled clinical study of antiviral therapy in the 2019-nCoV pneumonia. https://clinicaltrials.gov/ct2/show/NCT042550171/. 2020.
Not in our library
79.
Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382(19):1787-1799.
Not in our library10.1056/nejmoa2001282
80.
NIH Clinical Trials. Glucocorticoid therapy for COVID-19 critically ill patients with severe acute respiratory failure. https://clinicaltrials.gov/ct2/show/NCT04244591. 2020.
Not in our library
81.
US Food & Drug Administration. Coronavirus (COVID-19) Update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquin. 2020. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. Accessed 06/15/2020.
Not in our library
82.
Rismanbaf A, Zarei S. Liver and kidney injuries in COVID-19 and their effects on drug therapy; a letter to editor. Arch Acad Emerg Med. 2020;8(1):e17.
Not in our library
83.
Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: a critical appraisal. Int J Antimicrob Agents. 2020;56(3):106101.
Not in our library10.1016/j.ijantimicag.2020.106101
84.
Molina JM, Delaugerre C, Le Goff J, Mela-Lima B, Ponscarme D, Goldwirt L, et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. Med Mal Infect. 2020;50(4):384.
Not in our library10.1016/j.medmal.2020.03.006
85.
ter Meulen J, Bakker ABH, van den Brink EN, Weverling GJ, Martina BEE, Haagmans BL, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet. 2004;363(9427):2139-2141.
Not in our library10.1016/s0140-6736(04)16506-9
86.
Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo MR, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med. 2004;10(8):871-875.
Not in our library10.1038/nm1080
87.
Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants · 2006
No notice
88.
Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody · 2020
No notice
89.
Puoci F. "Monoclonal-type" plastic antibodies for COVID-19 treatment: what is the idea? J Funct Biomater. 2020;11(2):43.
Not in our library10.3390/jfb11020043
90.
Graham BS. Advances in antiviral vaccine development. Immunol Rev. 2013;255(1):230-242.
Not in our library10.1111/imr.12098
91.
Afrough B, Dowall S, Hewson R. Emerging viruses and current strategies for vaccine intervention. Clin Exp Immunol. 2019;196(2):157-166.
Not in our library10.1111/cei.13295
92.
Chumakov K, Benn CS, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? Science. 2020;368(6496):1187-1188.
Not in our library10.1126/science.abc4262
93.
Fidel PL Jr, Noverr MC. Could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with COVID-19 infection? mBio. 2020;11(3):e00907–20. 10.1128/mBio.00907-20.
Not in our library10.1128/mbio.00907-20
94.
Madan M, Pahuja S, Mohan A, Pandey RM, Madan K, Hadda V, et al. TB infection and BCG vaccination: are we protected from COVID-19? Public Health. 2020;185:91-92.
Not in our library10.1016/j.puhe.2020.05.042
95.
Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. Engl J Med. 2020;383:1920–1931. 10.1056/NEJMoa2022483.
Not in our library10.1056/nejmoa2022483
96.
Immunogenicity of a DNA vaccine candidate for COVID-19 · 2020
No notice
97.
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge · 2020
No notice
98.
Evaluation of the safety and immunogenicity of a SARS-CoV-2 rS (COVID-19) nanoparticle vaccine with/without matrix-M adjuvan. NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04368988.
Not in our library
99.
A study to assess safety, tolerability, and immunogenicity of V591 (COVID-19 vaccine) in healthy participants (V591–001). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04498247.
Not in our library
100.
Clinical trial to evaluate the safety and immunogenicitiy of the COVID-19 Vaccine (COVID-19-101). NIH U.S. National Library of Medicine; 2020 [cited 2020 08/22/2020]; Available from: https://clinicaltrials.gov/ct2/show/NCT04497298?term=TMV-083+vaccine&draw=2&rank=1.
Not in our library
101.
Ankcorn M, Gallacher J, Ijaz S, Taha Y, Harvala H, Maclennan S, et al. Convalescent plasma therapy for persistent hepatitis E virus infection. J Hepatol. 2019;71:434-438.
Not in our library10.1016/j.jhep.2019.04.008
102.
Wong SS, Yuen KY. The management of coronavirus infections with particular reference to SARS. J Antimicrob Chemother. 2008;62(3):437-441.
Not in our library10.1093/jac/dkn243
103.
van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374(1):33-42.
Not in our library10.1056/nejmoa1511812
104.
Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450-1451.
Not in our library10.1056/nejmc070359
105.
Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24(1):44-46.
Not in our library10.1007/s10096-004-1271-9
106.
Effectiveness of convalescent plasma therapy in severe COVID-19 patients · 2020
No notice
107.
Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-1589.
Not in our library10.1001/jama.2020.4783
108.
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA. 2020;323(16):1561-1562.
Not in our library10.1001/jama.2020.4940
109.
FDA. Recommendations for investigational COVID-19 convalescent plasma. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. 2020.
Not in our library
110.
Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides tocilizumab? SGP130Fc. Cytokine: X. 2020;2:100029.
Not in our library10.1016/j.cytox.2020.100029
111.
Anti-IL6R role in treatment of COVID-19-related ARDS · 2020
Not checked
112.
Caocci G, La Nasa G. Could ruxolitinib be effective in patients with COVID-19 infection at risk of acute respiratory distress syndrome (ARDS)? Ann Hematol. 2020;99(7):1675-1676.
Not in our library10.1007/s00277-020-04067-6
113.
Cascella M, Mauro I, De Blasio E, Crispo A, Del Gaudio A, Bimonte S, et al. Rapid and impressive response to a combined treatment with single-dose tocilizumab and NIV in a patient with COVID-19 pneumonia/ARDS. Medicina. 2020;56(8):377.
Not in our library10.3390/medicina56080377
114.
Altschuler EL, Kast RE. Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS). Med Hypotheses. 2020;141:109774.
Not in our library10.1016/j.mehy.2020.109774
115.
Macalino SJ, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res. 2015;38(9):1686-1701.
Not in our library10.1007/s12272-015-0640-5
116.
A perspective on multi‐target drug discovery and design for complex diseases · 2018
No notice
117.
Common and unique features of viral RNA-dependent polymerases · 2014
No notice
118.
Zhang WF, Stephen P, Theriault JF, Wang R, Lin SX. Novel coronavirus polymerase and nucleotidyl-transferase structures: potential to target new outbreaks. J Phys Chem Lett. 2020;11(11):4430-4435.
Not in our library10.1021/acs.jpclett.0c00571
119.
Qamar MTU, Alqahtani SM, Alamri MA, Chen LL. Structural basis of SARS-CoV-2 3CL(pro) and anti-COVID-19 drug discovery from medicinal plants. J Pharm Anal. 2020;10(4):313-319.
Not in our library10.1016/j.jpha.2020.03.009
120.
Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60(6):3277-3286.
Not in our library10.1021/acs.jcim.0c00179
121.
Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450-454.
Not in our library10.1038/nature02145
122.
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 · 2020
No notice
123.
Whisenant J, Burgess K. Blocking coronavirus 19 infection via the SARS-CoV-2 spike protein: initial steps. ACS Med Chem Lett. 2020;11(6):1076-1078.
Not in our library10.1021/acsmedchemlett.0c00233
124.
Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215-220.
Not in our library10.1038/s41586-020-2180-5
125.
Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell. 2020;181(4):894-904.
Not in our library10.1016/j.cell.2020.03.045
126.
Zhang G, Pomplun S, Loftis AR, Tan X, Loas A, Pentelute BL. Investigation of ACE2 N-terminal fragments binding to SARS-CoV-2 Spike RBD. bioRxiv. 2020. 10.1101/2020.03.19.999318.
Not in our library
127.
Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
Not in our library10.1056/nejmoa012354
128.
Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS. 2008;22:F1-F19.
Not in our library10.1097/qad.0b013e3282f4243b
129.
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV · 2020
No notice
130.
Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59(3):252-256.
Not in our library10.1136/thorax.2003.012658
131.
Lin S, Shen R, He J, Li X, Guo X. Molecular modeling evaluation of the binding effect of ritonavir, lopinavir and darunavir to severe acute respiratory syndrome coronavirus 2 proteases. bioRxiv. 2020. 10.1101/2020.01.31.929695
Not in our library
132.
Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines · 2011
No notice
133.
Liu Y, Miyoshi H, Nakamura M. Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer. 2007;120(12):2527-2537.
Not in our library10.1002/ijc.22709
134.
Jia F, Liu X, Li L, Mallapragada S, Narasimhan B, Wang Q. Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J Control Release. 2013;172(3):1020-1034.
Not in our library10.1016/j.jconrel.2013.10.012
135.
Majumder J, Taratula O, Minko T. Nanocarrier-based systems for targeted and site specific therapeutic delivery. Adv Drug Deliv Rev. 2019;144:57-77.
Not in our library10.1016/j.addr.2019.07.010
136.
Szunerits S, Barras A, Khanal M, Pagneux Q, Boukherroub R. Nanostructures for the inhibition of viral infections. Molecules. 2015;20(8):14051-14081.
Not in our library10.3390/molecules200814051
137.
Nanomaterials Designed for Antiviral Drug Delivery Transport across Biological Barriers · 2020
No notice
138.
Coleman CM, Liu YV, Mu H, Taylor JK, Massare M, Flyer DC, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169-3174.
Not in our library10.1016/j.vaccine.2014.04.016
139.
Huang X, Li M, Xu Y, Zhang J, Meng X, An X, et al. Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus. ACS Appl Mater Interfaces. 2019;11(22):19799-19807.
Not in our library10.1021/acsami.9b04240
140.
Li Y, Lu J, Han Y, Fan X, Ding S-W. RNA interference functions as an antiviral immunity mechanism in mammals. Science. 2013;342(6155):231-234.
Not in our library10.1126/science.1241911
141.
Shen AM, Minko T. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery. J Control Release. 2020;326:222-244.
Not in our library10.1016/j.jconrel.2020.07.011
142.
Garbuzenko OB, Kuzmov A, Taratula O, Pine SR, Minko T. Strategy to enhance lung cancer treatment by five essential elements: inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy. Theranostics. 2019;9(26):8362-8376.
Not in our library10.7150/thno.39816
143.
Kuzmov A, Minko T. Nanotechnology approaches for inhalation treatment of lung diseases. J Control Release. 2015;219:500-518.
Not in our library10.1016/j.jconrel.2015.07.024
144.
Savla R, Minko T. Nanotechnology approaches for inhalation treatment of fibrosis. J Drug Target. 2013;21(10):914-925.
Not in our library10.3109/1061186x.2013.829078
145.
Minko T, Stefanov A, Pozharov V. Selected contribution: lung hypoxia: antioxidant and antiapoptotic effects of liposomal alpha-tocopherol. J Appl Physiol. 2002;93(4):1550-1560.
Not in our library10.1152/japplphysiol.00007.2002
146.
Ivanova V, Garbuzenko OB, Reuhl KR, Reimer DC, Pozharov VP, Minko T. Inhalation treatment of pulmonary fibrosis by liposomal prostaglandin E2. Eur J Pharm Biopharm. 2013;84(2):335-344.
Not in our library10.1016/j.ejpb.2012.11.023
147.
Garbuzenko OB, Ivanova V, Kholodovych V, Reimer DC, Reuhl KR, Yurkow E, et al. Combinatorial treatment of idiopathic pulmonary fibrosis using nanoparticles with prostaglandin E and siRNA(s). Nanomedicine. 2017;13(6):1983-1992.
Not in our library10.1016/j.nano.2017.04.005
148.
Garbuzenko OB, Kbah N, Kuzmov A, Pogrebnyak N, Pozharov V, Minko T. Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers. J Control Release. 2019;296:225-231.
Not in our library10.1016/j.jconrel.2019.01.025
149.
El Kantar S, Nehmeh B, Saad P, Mitri G, Estephan C, Mroueh M, et al. Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites. Drug Discov Today. 2020. 10.1016/j.drudis.2020.08.002.
Not in our library10.1016/j.drudis.2020.08.002
150.
Chandna P, Saad M, Wang Y, Ber E, Khandare J, Vetcher AA, et al. Targeted proapoptotic anticancer drug delivery system. Mol Pharm. 2007;4(5):668-678.
Not in our library10.1021/mp070053o
151.
Taratula O, Garbuzenko OB, Chen AM, Minko T. Innovative strategy for treatment of lung cancer: targeted nanotechnology-based inhalation co-delivery of anticancer drugs and siRNA. J Drug Target. 2011;19(10):900-914.
Not in our library10.3109/1061186x.2011.622404
152.
Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, Minko T. Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A. 2010;107(23):10737-10742.
Not in our library10.1073/pnas.1004604107
153.
Kim H. Outbreak of novel coronavirus (COVID-19): what is the role of radiologists? Eur Radiol. 2020;30(6):3266-3267.
Not in our library10.1007/s00330-020-06748-2
154.
Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020;323(18):1843-1844.
Not in our library10.1001/jama.2020.3786
155.
Carter LJ, Garner LV, Smoot JW, Li Y, Zhou Q, Saveson CJ, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020;6(5):591-605.
Not in our library10.1021/acscentsci.0c00501
156.
Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 2020;92(6):589-594.
Not in our library10.1002/jmv.25725
157.
Team C-I. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861-868.
Not in our library10.1038/s41591-020-0877-5
158.
(FDA), Food and Drug Administration. Accelerated emergency use authorization (EUA) summary SARS-CoV-2 assay. Rutgers Clinical Genomics Laboratory. Nationwide Children’s Hospital; 2020. https://www.fda.gov/media/137423/download.
Not in our library
159.
Bhattarai KR, Kim HR, Chae HJ. Compliance with saliva collection protocol in healthy volunteers: strategies for managing risk and errors. Int J Med Sci. 2018;15(8):823-831.
Not in our library10.7150/ijms.25146
160.
VanGuilder HD, Vrana KE, Freeman WM. Twenty-five years of quantitative PCR for gene expression analysis. Biotechniques. 2008;44(5):619-626.
Not in our library10.2144/000112776
161.
Park GS, Ku K, Baek SH, Kim SJ, Kim SI, Kim BT, et al. Development of reverse transcription loop-mediated isothermal amplification assays targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). J Mol Diagn. 2020;22(6):729-735.
Not in our library10.1016/j.jmoldx.2020.03.006
162.
Seo G, Lee G, Kim MJ, Baek SH, Choi M, Ku KB, et al. Rapid detection of COVID-19 causative virus (SARS-CoV-2) in human nasopharyngeal swab specimens using field-effect transistor-based biosensor. ACS Nano. 2020;14(4):5135-5142.
Not in our library10.1021/acsnano.0c02823
163.
Wang J, Cai K, Zhang R, He X, Shen X, Liu J, et al. Novel one-step single-tube nested quantitative real-time PCR assay for highly sensitive detection of SARS-CoV-2. Anal Chem. 2020;13:9399-9404.
Not in our library10.1021/acs.analchem.0c01884
164.
Nuccetelli M, Pieri M, Grelli S, Ciotti M, Miano R, Andreoni M, et al. SARS-CoV-2 infection serology: a useful tool to overcome lockdown? Cell Death Dis. 2020;6:38.
Not in our library10.1038/s41420-020-0275-2
165.
Bryant JE, Azman AS, Ferrari MJ, Arnold BF, Boni MF, Boum Y, et al. Serology for SARS-CoV-2: apprehensions, opportunities, and the path forward. Sci Immunol. 2020;5(47):eabc6347.
Not in our library10.1126/sciimmunol.abc6347
166.
Li JX. Cellex qSARS-CoV-2 IgG/IgM Rapid Test. FDA, U.S. Food and Drug Administration. 2020. https://www.fda.gov/media/136625/download.
Not in our library
167.
Pan D, Pramanik M, Senpan A, Allen JS, Zhang H, Wickline SA, et al. Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J. 2011;25(3):875-882.
Not in our library10.1096/fj.10-171728
168.
Fraire JC, Perez LA, Coronado EA. Rational design of plasmonic nanostructures for biomolecular detection: interplay between theory and experiments. ACS Nano. 2012;6:3441-3452.
Not in our library10.1021/nn300474p
169.
Zeng J, Zhang Y, Zeng T, Aleisa R, Qiu Z, Chen Y, Huang J, Wang D, Yan Z, Yin Y. Anisotropic plasmonic nanostructures for colorimetric sensing. Nano Today. 2020;32:100855.
Not in our library10.1016/j.nantod.2020.100855
170.
Huang C, Wen T, Shi F-J, Zeng X-Y, Jiao Y-J. Rapid detection of IgM antibodies against the SARS-CoV-2 virus via colloidal gold nanoparticle-based lateral-flow assay. ACS Omega. 2020;5(21):12550-12556.
Not in our library10.1021/acsomega.0c01554
171.
Moitra P, Alafeef M, Dighe K, Frieman MB, Pan D. Selective naked-eye detection of SARS-CoV-2 mediated by N gene targeted antisense oligonucleotide capped plasmonic nanoparticles. ACS Nano. 2020;14:7617-7627.
Not in our library10.1021/acsnano.0c03822
172.
Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-PCR · 2020
No notice
173.
Lu R, Wu X, Wan Z, Li Y, Zuo L, Qin J, et al. Development of a novel reverse transcription loop-mediated isothermal amplification method for rapid detection of SARS-CoV-2. Virol Sin. 2020;35(3):344-347.
Not in our library10.1007/s12250-020-00218-1
174.
Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19 · 2020
No notice
175.
Detection of IgM and IgG antibodies in patients with coronavirus disease 2019 · 2020
No notice
176.
Cozzi D, Albanesi M, Cavigli E, Moroni C, Bindi A, Luvarà S, et al. Chest X-ray in new coronavirus disease 2019 (COVID-19) infection: findings and correlation with clinical outcome. La Radiol Med. 2020;125(8):730-737.
Not in our library10.1007/s11547-020-01232-9
177.
Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus disease 2019 (COVID-19): a systematic review of imaging findings in 919 patients. Am J Roentgenol. 2020;215(1):87-93.
Not in our library10.2214/ajr.20.23034
178.
Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest CT in diagnosis and management. Am J Roentgenol. 2020;214(6):1280-1286.
Not in our library10.2214/ajr.20.22954
179.
Buda N, Segura-Grau E, Cylwik J, Wełnicki M. Lung ultrasound in the diagnosis of COVID-19 infection - a case series and review of the literature. Adv Med Sci. 2020;65(2):378-385.
Not in our library10.1016/j.advms.2020.06.005
180.
Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296(2):E32-E40.
Not in our library10.1148/radiol.2020200642
181.
Fu F, Lou J, Xi D, Bai Y, Ma G, Zhao B, et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur Radiol 2020;30(10):5489–98. 10.1007/s00330-020-06920-8.
Not in our library10.1007/s00330-020-06920-8
182.
Lee EYP, Ng M-Y, Khong P-L. COVID-19 pneumonia: what has CT taught us? Lancet Infect Dis. 2020;20(4):384-385.
Not in our library10.1016/s1473-3099(20)30134-1
183.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.
Not in our library10.1016/s0140-6736(20)30183-5
184.
Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology. 2020;295(3):715-721.
Not in our library10.1148/radiol.2020200370

Cited by papers we hold 6

Severity-specific immune landscape of COVID-19 revealed by single-cell sequencing · 2025
Not checked
Comunicação em saúde sobre COVID-19 e Diabetes Mellitus em mídias sociais: verdadeiro e falso · 2022
Not checked
When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review · 2022
Not checked
SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines · 2022
No notice
Effect of internet-delivered cognitive behavioral therapy on insomnia in convalescent patients with COVID-19: Protocol for a systematic review and meta-analysis. · 2022
Not checked
A new perspective of hypothalamic disease: Shapiro's syndrome · 2022
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.